NEWS

For our visitors who seek the latest industry news and updates to keep abreast with the goings-on of the business on a global scale, Pharmaceutical Industry portal grants a dynamic and diverse feed of news items.

news

Recipharm has, based on the authorization granted by Recipharm's Annual General Meeting on 7 May, 2015, resolved to carry out a direct share issue of 2,250,000 Class B shares at subscription price of SEK 122.50 per share. The subscription price represents a discount of approximately 0.2 per cent compared to…

news

Belgian biotech group Galapagos said its experimental drug to treat bowel disease ulcerative colitis had failed to prove its efficacy in a medical trial and it would discontinue the program for that disease. While the drug GLPG1205 was well tolerated, Galapagos said it did not perform better than the placebo…

news

OncoMed Pharmaceuticals Inc lost nearly half its market value after independent investigators informed the company that its pancreatic cancer drug was unlikely to meet the main goal in a mid-stage study. The investigators told OncoMed that while the drug, tarextumab, had a clean safety profile, they had observed worsening response…

news

Swiss biotech giant Roche has initiated an internal investigation following reports in India that Avastin, its drug approved to treat several types of advanced cancers, had been used in certain eye ailments and damaged the vision of 15 patients in Gujarat. Avastin is widely prescribed "off label" for AMD or…

news

Federation of Medical Representatives of India State president P. Kameswara Rao on Sunday opposed 100 per cent foreign direct investment (FDI) in pharmaceutical companies, multiple taxation on medicines, the proposed modification in the Patent Act, demanding that corporate corruption be checked. The government announced that 35 per cent of the…

news

Japanese drug maker Astellas Pharma Inc. extended for a second time its $379 million buyout offer for Ocata Therapeutics Inc. of Marlborough, after it failed to win enough shareholder support. The tender offer, now set to expire 5 p.m. on Feb. 9, leaves the terms of $8.50-a-share deal unchanged. Astellas…

news

Danish drugmaker Novo Nordisk, the world's top insulin supplier, expects to be ahead of the pack now nuclear sanctions are lifted in Iran, thanks to a continuous presence and a pre-emptive investment plan. The country is an attractive target for Big Pharma seeking to sell new medicines to its large…

news

The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's cancer drug Kyprolis in combination with certain other therapies to treat patients with multiple myeloma. The agency also approved the drug as a single agent for patients with relapsed or refractory multiple myeloma who have received…

news

Alkermes Plc's depression drug failed in two late-stage studies, underlining the challenges drugmakers face in developing treatments for the condition that affects nearly 17 million Americans. Alkermes shares fell as much as 42.8 percent on Thursday, wiping $3.88 billion from the company's market value. Drugmakers including Eli Lilly and Co…

news

Three independent sources with direct knowledge of the deal share with ET NOW that Ahmedabad-based Claris Lifesciences has re-started deal talks to sell its injectables business. Sources close to the development suggest that Claris expects the valuations of the injectables business at over Rs 3,000 crores. Deal revival comes at…